ArticleMedComm2026
Efficacy and Safety of Co-Ablation Combined With Aintilimab for Metastatic Melanoma to the Liver (CryoCheck-001): A Phase II Trial.
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver metastasis is a key driver of immune tolerance in melanoma, limiting immune checkpoint inhibitor efficacy. This prospective single-arm phase II trial investigated the efficacy and safety of co-ablation combined with sintilimab for liver-metastatic melanoma (ChiCTR2200061591). Eligible patients received sintilimab (anti-PD-1, 200 mg every 3 weeks) for up to eight cycles alongside co-ablation. The primary endpoint was a 6-month progression-free survival (PFS) rate per Response Evaluation Criteria in Solid Tumors v1.1. Secondary endpoints included overall survival (OS), PFS time, and overall response rate (ORR). Between June 2022 and July 2025, 16 patients were enrolled. Three patients achieved a partial response (ORR 18.75%). The 6-month PFS rate was 31.25% (95% confidence interval [CI]: 15.1-64.6), with a median PFS of 3.94 months (95% CI: 2.77-14.30). The 12- and 24-month OS rates were 53.8% (95% CI: 33.7-86.0) and 28.7% (10.3-80.1), respectively; median OS was 16.67 months (95% CI: 7.50-NR). Grade ≥ 3 treatment-related adverse events occurred in 14 of 16 patients (87.5%), the most common being elevated liver enzyme levels. Co-ablation combined with sintilimab demonstrates a manageable safety profile and encouraging antitumor activity in patients with liver-metastatic melanoma, meriting further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.